2D 크로마토그래피 시장 : 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the 2D chromatography market size is projected to be USD 652.52 million in 2025, USD 695.88 million in 2026, and reach USD 965.75 million by 2031, growing at a CAGR of 6.75% from 2026 to 2031.

This report is Segmented by Product Type (2D Gas Chromatography, 2D Liquid Chromatography, and More), by Application (Pharmaceutical and Biotechnology Applications, Environmental, and More), by Detection Technology (Mass Spectrometry and More), by End User (Pharmaceutical & Biotechnology Companies and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global 2D Chromatography Market Trends and Insights

Rising Need for High-Resolution Separation in Complex Samples

Complex samples are becoming a core growth driver for the 2D chromatography market because co-elution problems now appear in biologics, proteomics extracts, environmental water samples, and food volatile analysis. In many of these matrices, a one-dimensional run can leave low-abundance compounds buried under stronger signals, which weakens impurity profiling, biomarker discovery, and trace contaminant detection. The technical case for multidimensional separation is strong because a 500-peak first dimension combined with a 50-peak second dimension yields a theoretical peak capacity of 25,000 compounds. That level of separation matters when laboratories must show that difficult impurity pairs or closely related analytes have been resolved well enough for regulatory or scientific review. As a result, the 2D chromatography market is benefiting from replacement demand as laboratories move from legacy single-dimension platforms toward heart-cut or comprehensive configurations. The same shift is also widening adoption across regulated and research settings because the separation problem is no longer limited to specialist laboratories.

High Instrument and Method Validation Cost

High capital cost remains one of the clearest restraints on the 2D chromatography market, especially for mid-sized contract laboratories, public testing agencies, and research groups with fixed procurement cycles. Comprehensive LCXLC-MS or GCXGC-TOFMS systems require not only instrument purchase but also software licenses, accessories, service coverage, and ongoing consumable commitments. The validation side is equally demanding because ICH Q2(R2) requires repeatability, intermediate precision, linearity, specificity, and robustness evidence across the full analytical procedure. In practice, that means the cost difference versus one-dimensional HPLC is much larger than the instrument list price alone suggests. The result is that the 2D chromatography market still concentrates fastest adoption among organizations that can absorb both acquisition cost and method qualification time. This also leaves a sizable middle tier of users interested in the capability but slower to commit to full-system deployment.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of Biologics, Proteomics, and Metabolomics Workflows
2. Tightening Quality and Impurity Profiling Requirements in Regulated Testing
3. Growth of Hyphenated 2D Chromatography and Mass Spectrometry Workflows
4. Shortage of Skilled Analysts and System Integrators

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

2D liquid chromatography held 52.15% share in 2025, which made it the largest product category in the 2D chromatography market. The segment is also projected to expand at 7.38% CAGR through 2031, which keeps it ahead of other product types on both current scale and forward momentum. Its strength comes from broad compatibility with proteins, peptides, and polar metabolites, especially in workflows tied to biopharma quality control and omics analysis. The installed base is also being supported by online valve-switching formats that reduce analysis cycle time and make routine deployment more feasible than earlier generations. This keeps 2D-LC at the core of the 2D chromatography industry as laboratories seek more practical ways to move beyond single-dimension HPLC. It also helps explain why the segment remains the default entry point for buyers who need multidimensional separation but want operational familiarity.

2D gas chromatography still has an important role in petrochemical profiling, flavor and fragrance work, and environmental screening, where volatile or semi-volatile compounds dominate the matrix. That base is stable because GCXGC paired with TOFMS continues to serve hydrocarbon speciation and non-target contaminant analysis with strong performance in complex samples. A 2025 study also showed that multi-2D LCXLC using a pentafluorophenyl first dimension and 2 complementary second-dimension columns delivered a 91% gain in peak capacity and 30% better peak distribution than standard LCXLC for European medicinal plants. This supports the view that hybrid and multi-modal systems are becoming a meaningful high-end growth layer within the 2D chromatography market rather than a niche experiment. Shimadzu's Nexera UC-2D platform also shows how vendors are linking LCXLC with supercritical fluid chromatography to widen use in chiral separations and biopolymer analysis. The broader pattern is that the 2D chromatography industry is deepening around established 2D-LC demand while also widening into more configurable system architectures.

Pharmaceutical and biotechnology applications generated 35.37% share in 2025, which gave them the largest application position in the 2D chromatography market size. Life science research is forecast to record the fastest CAGR at 8.01% through 2031, supported by proteomics, metabolomics, and multi-omics programs that require higher peak capacity than one-dimensional systems can provide. The difference between the two leaders is important because it shows how the 2D chromatography market is being supported by both routine regulated demand and expanding discovery demand. Drug release testing, stability studies, and impurity profiling continue to give pharmaceutical and biotechnology laboratories a steady workflow base. At the same time, grant-backed academic centers and specialist institutes are creating new placements for deeper proteome coverage, biomarker discovery, and systems biology analysis. This makes application growth more balanced than a purely pharma-dependent cycle.

Environmental analysis is also advancing because PFAS monitoring and other non-target screening demands are pushing laboratories toward more capable GCXGC and LCXLC workflows. Food and beverage testing remains relevant for flavor volatiles, pesticide residues, mycotoxins, and adulterant measurement under evolving safety thresholds. Petrochemical and natural gas analysis contributes to a more stable demand, since comprehensive GC-based workflows are already well established for hydrocarbon speciation and process control. The life science research case is being strengthened by expanding evidence on automated and high-content multidimensional methods, including work that supports systematic multi-component profiling of complex formulations with online comprehensive 2D-LC-QTOF-MS. That kind of evidence helps the 2D chromatography market move from expert-only adoption toward broader institutional use across pharmaceutical science, translational medicine, and advanced natural product characterization. It also reduces the risk that future growth will depend on a single end application.

Complete Report Scope:

• By Product Type
  • 2D Gas Chromatography
  • 2D Liquid Chromatography
  • Hybrid and Multi-Modal Systems
• By Application
  • Pharmaceutical and Biotechnology Applications
  • Environmental Analysis
  • Food and Beverage Testing
  • Life Science Research
  • Petrochemical and Natural Gas Analysis
  • Other Applications (Forensic Science, Clinical Toxicology, etc.)
• By Detection Technology
  • Mass Spectrometry
  • Flame Ionization Detection
  • UV and Visible Detection
  • Others (Charged Aerosol Detector (CAD), Fluorescence Detection (FLD), etc.)
• By End Use
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Clinical and Diagnostic Laboratories
  • Environmental Testing Laboratories
  • Food and Beverage Laboratories
  • Petrochemical and Industrial Testing Facilities
  • Other End Uses (CDMOs, CROs, etc.)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.23% share in 2025, giving the region the largest position in the 2D chromatography market. The region benefits from a dense biopharmaceutical R&D base, a large installed analytical instrument fleet, and a compliance culture that supports faster adoption of higher-resolution methods. The United States remains the center of that demand because biologics development, host cell protein analysis, and LC-MS/MS-based quality control work continue to expand in both originator and outsourced settings. Regulatory frameworks for analytical procedure development and biological product characterization also reinforce the need for stronger method defensibility and orthogonal separation. This keeps the 2D chromatography market well supported across pharmaceutical companies, contract laboratories, and academic medical centers that contribute to technology development. Canada adds a smaller but stable base through research institutions and regulated testing laboratories that increasingly require advanced analytical platforms.

Europe remained the second-largest regional block in the 2D chromatography market, supported by pharmaceutical manufacturing depth in Germany, France, Italy, and the UK. Public research modernization and advanced omics programs are also helping sustain demand for 2D-LC platforms in university and research institute settings. The region's demand profile is shaped by strong biologics quality expectations and a continued willingness to invest in high-specification analytical infrastructure when workflow benefits are clear. Germany stands out because solvent efficiency and sustainability are becoming more relevant in institutional procurement, which favors platforms designed to reduce solvent burden over long operating cycles. This makes Europe an important market for both premium system replacement and specialized hybrid configurations that serve advanced separations.

Asia-Pacific is projected to grow at 8.45% CAGR through 2031, which makes it the fastest-expanding regional block in the 2D chromatography market. China is the main volume engine because biosimilar manufacturing scale-up and pharmacopoeial recognition of heart-cut and comprehensive 2D-LC are reducing hesitation around adoption. Agilent's simultaneous Infinity III LC Series launch in Dalian, the United States, and Germany also signaled that China now ranks as a first-tier launch market for high-precision analytical instruments. India, Japan, and South Korea add further momentum through contract research, orthogonal characterization needs, and biosimilar quality investment, while Southeast Asia and Australia are benefiting from broader GCxGC deployment in food, environmental, fragrance, and petrochemical testing.

1. Agilent Technologies
2. Bio-Rad Laboratories
3. Bruker
4. Danaher
5. Gilson
6. GL Sciences Inc.
7. Hitachi
8. JASCO Corporation
9. KNAUER Wissenschaftliche Gerate GmbH
10. LECO
11. Merck
12. PerkinElmer
13. Phenomenex, Inc.
14. Restek
15. Sartorius
16. SepSolve Analytical Ltd.
17. Shimadzu
18. Thermo Fisher Scientific
19. Trajan Scientific and Medical
20. Waters Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Need for High-Resolution Separation in Complex Samples
  • 4.2.2 Expansion of Biologics, Proteomics, and Metabolomics Workflows
  • 4.2.3 Tightening Quality and Impurity Profiling Requirements in Regulated Testing
  • 4.2.4 Growth of Hyphenated 2D Chromatography and Mass Spectrometry Workflows
  • 4.2.5 Miniaturized and Automated Platforms Lowering Method Development Friction
  • 4.2.6 AI-Assisted Peak Deconvolution and Retention Alignment Improving Analytical Throughput
• 4.3 Market Restraints
  • 4.3.1 High Instrument and Method Validation Cost
  • 4.3.2 Shortage of Skilled Analysts and System Integrators
  • 4.3.3 Integration Complexity With Legacy Laboratory Workflows
  • 4.3.4 Validation Burden for Regulated and Multi-Site Deployments
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Product Type
  • 5.1.1 2D Gas Chromatography
  • 5.1.2 2D Liquid Chromatography
  • 5.1.3 Hybrid and Multi-Modal Systems
• 5.2 By Application
  • 5.2.1 Pharmaceutical and Biotechnology Applications
  • 5.2.2 Environmental Analysis
  • 5.2.3 Food and Beverage Testing
  • 5.2.4 Life Science Research
  • 5.2.5 Petrochemical and Natural Gas Analysis
  • 5.2.6 Other Applications (Forensic Science, Clinical Toxicology, etc.)
• 5.3 By Detection Technology
  • 5.3.1 Mass Spectrometry
  • 5.3.2 Flame Ionization Detection
  • 5.3.3 UV and Visible Detection
  • 5.3.4 Others (Charged Aerosol Detector (CAD), Fluorescence Detection (FLD), etc.)
• 5.4 By End Use
  • 5.4.1 Pharmaceutical and Biotechnology Companies
  • 5.4.2 Academic and Research Institutes
  • 5.4.3 Clinical and Diagnostic Laboratories
  • 5.4.4 Environmental Testing Laboratories
  • 5.4.5 Food and Beverage Laboratories
  • 5.4.6 Petrochemical and Industrial Testing Facilities
  • 5.4.7 Other End Uses (CDMOs, CROs, etc.)
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Agilent Technologies, Inc.
  • 6.3.2 Bio-Rad Laboratories, Inc.
  • 6.3.3 Bruker Corporation
  • 6.3.4 Danaher Corporation
  • 6.3.5 Gilson, Inc.
  • 6.3.6 GL Sciences Inc.
  • 6.3.7 Hitachi High-Tech Corporation
  • 6.3.8 JASCO Corporation
  • 6.3.9 KNAUER Wissenschaftliche Gerate GmbH
  • 6.3.10 LECO Corporation
  • 6.3.11 Merck KGaA
  • 6.3.12 PerkinElmer, Inc.
  • 6.3.13 Phenomenex, Inc.
  • 6.3.14 Restek Corporation
  • 6.3.15 Sartorius AG
  • 6.3.16 SepSolve Analytical Ltd.
  • 6.3.17 Shimadzu Corporation
  • 6.3.18 Thermo Fisher Scientific Inc.
  • 6.3.19 Trajan Scientific and Medical
  • 6.3.20 Waters Corporation

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-space and Unmet-Need Assessment